{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:38Z","timestamp":1793915678147,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40265-025-02211-y","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:15:51Z","timestamp":1754648151000},"page":"1185-1192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nipocalimab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"4","key":"2211_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG, et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105(4):1031\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427\u201338.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2211_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJMoa2314466","volume":"391","author":"KJ Moise Jr","year":"2024","unstructured":"Moise KJ Jr, Ling LE, Oepkes D, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391(6):526\u201337.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2211_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","volume":"83","author":"J Gottenberg","year":"2024","unstructured":"Gottenberg J, Sivils K, Campbell K, et al. Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary sjogren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS) [abstract no. LBA0010]. Ann Rheum Dis. 2024;83(Suppl 1):240.","journal-title":"Ann Rheum Dis"},{"issue":"e004278","key":"2211_CR5","first-page":"1","volume":"10","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Schett G, Huizinga TW, et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024;10(e004278):1\u201312.","journal-title":"RMD Open"},{"issue":"2","key":"2211_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105\u201316.","journal-title":"Lancet Neurol"},{"key":"2211_CR7","unstructured":"Janssen Pharmaceutical Companies. IMAAVYTM (nipocalimab-aahu) injection, for intravenous use; US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf. Accessed 23 May 2025."},{"key":"2211_CR8","unstructured":"Johnson & Johnson. Johnson Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) [media release]. https:\/\/www.multivu.com\/johnson-johnson\/9331651-en-johnson-johnson-receives-fda-approval-imaavy-nipocalimab-aahu. Accessed 30 Apr 2025."},{"key":"2211_CR9","unstructured":"Janssen. J&J files nipocalimab for generalized myasthenia gravis in Japan [media release]. https:\/\/pj.jiho.jp\/article\/252421. Accessed 31 Jan 2025."},{"key":"2211_CR10","unstructured":"Janssen. Johnson Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis [media release]. https:\/\/www.investor.jnj.com\/. Accessed 12 Sept 2024."},{"key":"2211_CR11","unstructured":"Momenta Pharmaceuticals. Momenta pharmaceuticals announces expiration of Hart-Scott-Rodino waiting period in connection with proposed sale to Johnson & Johnson [media release]. http:\/\/www.momentapharma.com. Accessed 15 Sept 2020."},{"issue":"Suppl 9","key":"2211_CR12","first-page":"4616","volume":"76","author":"K Sivils","year":"2024","unstructured":"Sivils K, Leonardo S, Li H, et al. Pharmacodynamic effects of nipocalimab on disease biomarkers in patients with moderate-to-severe active Sjogren\u2019s disease: results from a multicenter, randomized, double-blinded, placebo-controlled phase 2 study [abstract no. 2294]. Arthritis Rheumatol. 2024;76(Suppl 9):4616\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2211_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-024-01380-0","volume":"44","author":"N Matsushima","year":"2024","unstructured":"Matsushima N, Shibata S, Leu JH, et al. Pharmacokinetics and pharmacodynamics of nipocalimab, a neonatal Fc receptor blocker, in healthy Japanese volunteers. Clin Drug Investig. 2024;44(8):587\u201399.","journal-title":"Clin Drug Investig"},{"key":"2211_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study. Neurology. 2024;102:1\u201314.","journal-title":"Neurology"},{"issue":"3","key":"2211_CR15","first-page":"676","volume":"70","author":"J Strober","year":"2024","unstructured":"Strober J, Black S, Ramchandren S, et al. Safety and effectiveness of nipocalimab in adolescent participants in the open label phase 2\/3 VIBRANCE-MG clinical study [abstract no. MG66]. Muscle Nerve. 2024;70(3):676.","journal-title":"Muscle Nerve"},{"issue":"7","key":"2211_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1055\/a-2404-8089","volume":"42","author":"Y Komatsu","year":"2025","unstructured":"Komatsu Y, Verweij E, Tiblad E, et al. Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn. Am J Perinatol. 2025;42(7):842\u201353.","journal-title":"Am J Perinatol"},{"issue":"Suppl 1","key":"2211_CR17","doi-asserted-by":"publisher","first-page":"1193.1","DOI":"10.1182\/blood-2024-211393","volume":"144","author":"JB Bussel","year":"2024","unstructured":"Bussel JB, Baker P, Lam E, et al. Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or ivig in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FREESIA-3) [abstract no. 1193.1 plus poster]. Blood. 2024;144(Suppl 1):1193.1.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2211_CR18","first-page":"43","volume":"201","author":"T Vaikunthanathan","year":"2023","unstructured":"Vaikunthanathan T, Murakhovskaya I, Fattizzo B, et al. Designing ENERGY: a phase 2\/3 study of nipocalimab in warm autoimmune haemolytic anaemia [abstract no. BSH23-PO112]. Br J Haematol. 2023;201(Suppl 1):43.","journal-title":"Br J Haematol"},{"issue":"17 Suppl 2","key":"2211_CR19","first-page":"8.006","volume":"100","author":"L Ford","year":"2023","unstructured":"Ford L, Wong J, Youssef E, et al. A phase 2\/3 placebo-controlled, parallel group, randomized withdrawal study to evaluate the efficacy and safety of nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy: the ARISE study [abstract no. P14-8.006]. Neurology. 2023;100(17 Suppl 2):8.006.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"2211_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1136\/annrheumdis-2024-eular.3020","volume":"83","author":"C Najem","year":"2024","unstructured":"Najem C, Craig J, Christopher Stine L, et al. A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA): study design [abstract no. AB0250]. Ann Rheum Dis. 2024;83(Suppl 1):1365.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"2211_CR21","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/annrheumdis-2023-eular.2219","volume":"82","author":"F Liu-Walsh","year":"2023","unstructured":"Liu-Walsh F, Hartingsveldt BV, Zuraw Q, et al. Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study [abstract no. AB0548]. Ann Rheum Dis. 2023;82(Suppl 1):1472\u20133.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02211-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:23:31Z","timestamp":1757258611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02211-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"30 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Fung is a salaried employee of Adis International Ltd.\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}